Mira Pharmaceuticals announces insights from presentation on MIRA1a

MIRA Pharmaceuticals revealed insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville’s Christine Lee Brown Envirome Institute’s Grand Rounds from Dr. Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals and Adjunct Faculty member at the Johns Hopkins School of Medicine. Dr. Kaplin’s presentation covered his research on psychotropic drug development, specifically examining the contrasting properties of THC and MIRA1a, a novel, cutting-edge THC analog. Key Findings from Dr. Kaplin’s Presentation: Overcoming Biphasic Response: While THC exhibited limitations with a biphasic response, being therapeutic at low doses but toxic at high doses, MIRA1a showcased unparalleled stability, even at high doses, without any toxic side effects. Unprecedented Cognitive Boost: MIRA1a demonstrated a doubling of the performance of normal adult mice in learning and memory tests, showcasing MIRA1a’s potential to elevate cognitive abilities beyond normal thresholds.